Foster & Motley Inc. Has $7.54 Million Stake in Johnson & Johnson $JNJ

Foster & Motley Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,385 shares of the company’s stock after buying an additional 998 shares during the quarter. Foster & Motley Inc.’s holdings in Johnson & Johnson were worth $7,544,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Chevy Chase Trust Holdings LLC grew its position in Johnson & Johnson by 0.6% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,401,388 shares of the company’s stock valued at $214,062,000 after purchasing an additional 9,043 shares during the period. Arista Wealth Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $1,489,000. Sage Private Wealth Group LLC grew its position in Johnson & Johnson by 13.0% in the 2nd quarter. Sage Private Wealth Group LLC now owns 3,304 shares of the company’s stock valued at $505,000 after purchasing an additional 381 shares during the period. Stratos Investment Management LLC grew its position in Johnson & Johnson by 5.8% in the 2nd quarter. Stratos Investment Management LLC now owns 19,948 shares of the company’s stock valued at $3,047,000 after purchasing an additional 1,094 shares during the period. Finally, Oxbow Advisors LLC grew its position in Johnson & Johnson by 2.9% in the 2nd quarter. Oxbow Advisors LLC now owns 44,663 shares of the company’s stock valued at $6,822,000 after purchasing an additional 1,258 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on JNJ. Citigroup lifted their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. UBS Group raised their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Finally, Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $199.59.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $193.27 on Friday. The stock has a market cap of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $180.49 and its two-hundred day simple moving average is $164.86.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.